CXCR4 and adrenal cortex carcinoma: Similarly, in another study of thirty patients with histologically proven advanced metastatic ACC who underwent 18F-FDG PET/CT and 68Ga-Pentixafor to evaluate suitability for CXCR4-targeted therapy, 18F-FDG PET/CT provided a superior detection rate than 68Ga-Pentixafor PET/CT with a visually higher uptake in 43% of patients [86].